A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Status:
Withdrawn
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and
Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR
TKI.
Phase:
Phase 3
Details
Lead Sponsor:
Hangzhou ACEA Pharmaceutical Research Co., Ltd. Hangzhou ACEA Pharmaceutical Research Co.,Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences